Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;54(3):647-659.
doi: 10.1007/s11255-021-02919-2. Epub 2021 Jul 5.

Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania

Cristiana-Elena Vlad #  1   2 , Liliana Foia  3   4 , Mariana Pavel-Tanasa #  2 , Vasilica Toma  2 , Laura Florea #  1   2 , Luminita Voroneanu  2 , Mugurel Apetrii  2 , Gianina Dodi  2 , Adrian Covic  1   2   5
Affiliations

Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania

Cristiana-Elena Vlad et al. Int Urol Nephrol. 2022 Mar.

Abstract

Purpose: The aim of this prospective cohort study was: to identify the association between different biomarkers [proprotein convertase subtilisin/kexin 9-PCSK9, lipoprotein(a)-Lp(a) and high-sensitivity C-reactive protein-hsCRP] and the cardiovascular events; to evaluate the relationship between the 3 biomarkers mentioned above and the renal outcomes that contributed to end-stage renal disease (ESRD).

Methods: We studied 110 patients with chronic kidney disease (CKD) stages 2 to 4. The identification of the new cardiovascular events and the renal outcomes were performed by clinical and paraclinical explorations.

Results: 350 patients were examined and 110 (31.4%) were included in this study. The mean age was 55.6 ± 10.9 years, with a higher number of men compared to women. The CKD patients with de novo cardiovascular events and new renal outcome during the study, had significantly increased values of total cholesterol (TC), low density cholesterol lipoprotein (LDL-C) at 6 and 12 months and higher levels of Lp(a), PCSK9, hsCRP and low ankle-brachial index (ABI) and ejection fraction (EF) values compared to patients without cardiovascular and renal events. In CKD patients, PCSK9 > 220 ng/mL was a predictor of cardiovascular events, while the EF < 50% was a predictor for renal outcomes. For CKD patients with PCSK9 > 220 ng/mL and hsCRP > 3 mg/L levels, the time-interval for the new cardiovascular and renal events occurrence were significantly decreased compared to patients displaying low values of these biomarkers.

Conclusion: The results of this study show that PCSK9 > 220 ng/mL was predictor for cardiovascular events, while EF < 50% was predictor for CKD progression to ESRD. PCSK9 > 220 ng/mL and hsCRP > 3 mg/L were associated with the occurrence of renal and cardiovascular events earlier.

Keywords: Atherosclerotic cardiovascular disease; Cardiovascular events; Chronic kidney disease; Dyslipidemia; High‐sensitivity C‐reactive protein; Lipoprotein(a); Proprotein convertase subtilisin/kexin 9; Renal outcome.

PubMed Disclaimer

References

    1. Mikolasevic I, Zutelija M, Mavrinac V, Orlic L (2017) Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis 10:35–45 - DOI
    1. Vlad C, Burlacu A, Florea L, Artene B, Badarau S, Covic A, Ureche C, Scripcariu D, Foia L, Covic A (2019) A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives. Int Urol Nephrol 51(7):1173–1189 - DOI
    1. Rahman T, Hamzan NS, Mokhsin A, Rahmat R, Ibrahim ZO, Razali R, Thevarajah M, Nawawi H (2017) Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members: a case control study. Lipids Health Dis 16(1):81 - DOI
    1. Parsons DS, Reaveley DA, Pavitt DV, Misra M, Brown EA (2003) Lipoprotein(a) levels in those with high molecular weight apo(a) isoforms may remain low in a significant proportion of patients with end-stage renal disease. Nephrol Dial Transplant 18(9):1848–1853 - DOI
    1. Gragnano F, Calabro P (2018) Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis 269:219–228 - DOI

LinkOut - more resources